folder

T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia

Authors

  • J. Westermann
  • C. Schlimper
  • G. Richter
  • J. Mohm
  • B. Doerken
  • A. Pezzutto

Journal

  • British Journal of Haematology

Citation

  • Br J Haematol 125 (2): 213-216

Abstract

  • In chronic myeloid leukaemia (CML), peptides from the fusion region of bcr3/abl2 are likely to play a role in anti-leukaemic T cell immunity. We investigated whether T cells that recognize bcr/abl fusion peptides could be detected in healthy donors and CML patients. T cell responses against bcr3/abl2 fusion peptides were analysed by {gamma}-interferon enzyme-linked immunospot assays after prestimulation of peripheral blood mononuclear cells in the presence of anti-CD3-antibodies and interleukin-2. Our results suggest that the T cell repertoire contains bcr3/abl2-reactive T cells in CML patients who are in cytogenetic remission, but also in some healthy individuals.


DOI

doi:10.1111/j.1365-2141.2004.04873.x